Ratings electroCore, Inc.

Equities

ECOR

US28531P2020

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-02 pm EDT			5-day change	1st Jan Change
6.12 ^USD	+1.32%		+8.32%	+2.82%

Apr. 30	ElectroCore, Inc. Announces Results of Truvaga Plus Consumer Study	CI
Apr. 08	ElectroCore, Inc. Announces the Launch of Truvaga Plus® for General Wellness	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Over the last twelve months, the sales forecast has been frequently revised upwards.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
ELECTROCORE, INC.	+2.82%	36.74M	D+
SHOCKWAVE MEDICAL, INC.	+73.17%	12.38B	B-
PENUMBRA, INC.	-18.08%	7.99B	C+
MASIMO CORPORATION	+16.24%	7.21B	C-
GETINGE AB	+3.43%	5.79B	B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+11.77%	5.35B	D+
APT MEDICAL INC.	+29.65%	4.63B	-
ASAHI INTECC CO., LTD.	-17.74%	4.17B	B-
INARI MEDICAL, INC.	-35.34%	2.44B	C
SKAN GROUP AG	+2.72%	2.03B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes